Cellectar Biosciences, Inc. (CLRB) Reports 8+ Year Complete Response in DLBCL Case on Iopofosine I 131

What happened

Cellectar Biosciences reported that a heavily pretreated DLBCL patient had a complete response lasting more than eight years after a single dose of iopofosine I 131, and it plans to begin dosing a confirmatory Phase 3 WM study in Q1 2027 while targeting an H1 2027 FDA filing.

Confirmed

Global impact / market context

A long-lasting complete response, meaning the cancer became undetectable, in a hard-to-treat patient supports the drug's potential and could improve investor views of the company's platform. The planned Phase 3 study and FDA filing set expected milestones that may shape future valuation and financing.

Analyst inference

The news is modest but positive clinical evidence that fits earlier WM data and shows late-stage progress. A larger dataset, peer-reviewed publication, Phase 3 results, or regulatory feedback would be needed to make it a major catalyst for the stock.

Analyst inference

What to watch

1. Cellectar expects to start dosing its confirmatory Phase 3 WM study in Q1 2027, which is a registrational study intended to support approval. Confirmed
2. The company targets an H1 2027 FDA filing, and investors should watch whether that submission timeline holds or slips. Proposed
3. Watch for a larger dataset, peer-reviewed publication, and Phase 3 readouts or regulatory feedback, which could turn supportive evidence into a major catalyst. Analyst inference

Evidence

• globenewswire.com